Study on the Potential of Small Molecules as Drug Targets for Cancer

Target Name: CASC17

NCBI ID: G101928165

CASC17

Other Name(s): Cancer susceptibility 17 | cancer susceptibility 17 | LINC00600

Study on the Potential of Small Molecules as Drug Targets for Cancer

Cancer Susceptibility 17 (CASC17) is a protein that is expressed in a variety of tissues throughout the body, including the skin, hair, and nails. It is a key regulator of cell growth and differentiation, and has been implicated in the development and progression of many types of cancer. Despite its importance, little is known about CASC17 and its potential as a drug target or biomarker.

CASC17 is a 21-kDa protein that is expressed in a variety of tissues throughout the body, including the skin, hair, and nails. It is a key regulator of cell growth and differentiation, and has been implicated in the development and progression of many types of cancer. The protein is composed of 17 distinct subunits that are held together by disulfide bonds.

One of the most interesting features of CASC17 is its role in cell signaling.CASC17 has been shown to play a role in a variety of signaling pathways, including the NF-kappa pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway. These pathways are involved in regulating cell growth, differentiation, and survival, and are often disrupted in cancer cells.

CASC17 has also been shown to be involved in the regulation of cell adhesion.CASC17 is a member of the cadherin family of transmembrane proteins, and is involved in the formation of tight junctions, which are a type of cell adhesion structure. tight junctions are responsible for maintaining the integrity of the intercellular space and are critical for the proper functioning of many tissues.

In addition to its role in cell signaling and cell adhesion, CASC17 has also been shown to be involved in the regulation of cell survival.CASC17 has been shown to play a role in the inhibition of cell-cycle progression, which is the process by which cells divide and grow. This is important for the regulation of cell growth and the development of cancer.

CASC17 has also been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed.CASC17 has been shown to play a role in the inhibition of angiogenesis, which is important for the development of many types of cancer.

Despite its importance, little is known about CASC17 and its potential as a drug target or biomarker.CASC17 is not a well-studied protein, and there are few research studies that have focused on its role in cancer.

One potential way to study the role of CASC17 as a drug target is through the use of small molecules.CASC17 is a protein that is expressed in a variety of tissues throughout the body, and is therefore a potential target for small molecules that can modulate its activity.

One of the most promising small molecules that may be able to modulate the activity of CASC17 is the drug sunitinib.Sunitinib is a potent inhibitor of the tyrosine kinase activity of platelet-derived growth factor (PDGF). PDGF is a potent regulator of cell growth and survival, and is often disrupted in cancer cells.

Sunitinib has been shown to be an effective inhibitor of PDGF, and may be able to modulate the activity of CASC17 in a similar way.Sunitinib has been shown to inhibit the tyrosine kinase activity of PDGF, which is the activity that is responsible for the regulation of cell growth and survival. This may mean that sunitinib could be an effective way to

Protein Name: Cancer Susceptibility 17

The "CASC17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CASC17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets